1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC).

Authors :: Schram, A.
Goto, K.
Kim, D-W.
Hollebecque, A.
Rha, S.Y.
Nishino, K.
Duruisseaux, M.
Umemoto, K.
Park, J.O.
Leighl, N.
Macarulla, T.
Liu, S.V.
Al-Hallak, M.N.
Cleary, J.
Neuzillet, C.
Goto, Y.
Joe, A.K.
Adeyemi, S.
Jauhari, S.
Drilon, A.
Source :: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS756-S757. 2p.
Publication Year :: 2023

Subjects :: *NON-small-cell lung carcinoma
*BISPECIFIC antibodies
*NEUREGULINS

Full Text Access

Tools